ライフサイエンスコーパス: multidrug-resistant tuberculosis

1 quiline and clofazimine, key drugs to combat multidrug resistant tuberculosis.

2 ey had been exposed to an index patient with multidrug-resistant tuberculosis.

3 ring their life and 13 (17%) had undiagnosed multidrug-resistant tuberculosis.

4 pert MTB/RIF assay to identify patients with multidrug-resistant tuberculosis.

5 d those of the purported source patient with multidrug-resistant tuberculosis.

6 ds of death among HIV-positive patients with multidrug-resistant tuberculosis.

7 roups reflects the local risk of transmitted multidrug-resistant tuberculosis.

8 riteria for the systematic review of risk of multidrug-resistant tuberculosis.

9 shorten the duration of therapy and to treat multidrug-resistant tuberculosis.

10 addition of clofazimine in a mouse model of multidrug-resistant tuberculosis.

11 e antimycobacterial drugs currently used for multidrug-resistant tuberculosis.

12 d mortality risk in HIV-positive adults with multidrug-resistant tuberculosis.

13 elamanid could enhance treatment options for multidrug-resistant tuberculosis.

14 therapy for contacts of cases of infectious multidrug-resistant tuberculosis.

15 e conversion at 2 months among patients with multidrug-resistant tuberculosis.

16 second-line therapy for patients who develop multidrug-resistant tuberculosis.

17 tuberculosis; the remaining 603 patients had multidrug-resistant tuberculosis.

18 nteresting possibilities in the treatment of multidrug-resistant tuberculosis.

19 cin, is now widely accepted for treatment of multidrug-resistant tuberculosis.

20 of second-line therapy for the treatment of multidrug-resistant tuberculosis.

21 2 percent continued to receive treatment for multidrug-resistant tuberculosis.

22 cterial agents being used clinically against multidrug-resistant tuberculosis.

23 men that has revolutionized the treatment of multidrug-resistant tuberculosis.

24 eceiving a longer individualized regimen for multidrug-resistant tuberculosis.

25 tly approved medication for the treatment of multidrug-resistant tuberculosis.

26 ose isoniazid may be efficacious in treating multidrug-resistant tuberculosis.

27 by the success of bedaquiline in combatting multidrug-resistant tuberculosis.

28 recently approved drugs for the treatment of multidrug-resistant tuberculosis.

29 gement and improve outcomes of patients with multidrug-resistant tuberculosis.

30 increased transmission and amplification of multidrug-resistant tuberculosis.

31 h all-cause mortality among US patients with multidrug-resistant tuberculosis.

32 th a potential for immunotherapy in treating multidrug-resistant tuberculosis.

33 for the development of novel drugs to tackle multidrug-resistant tuberculosis.

34 ctinomycin antibiotic essential for treating multidrug-resistant tuberculosis.

35 terial, used in the treatment of adults with multidrug-resistant tuberculosis.

36 ment were critical to limiting the spread of multidrug- resistant tuberculosis.

37 Of 608 patients with multidrug resistant tuberculosis, 29 (4.8%) patients had

38 Multidrug-resistant tuberculosis, a disease caused by My

39 ; 95% confidence interval, 0.18-0.48) and to multidrug-resistant tuberculosis (adjusted hazard ratio,

40 one to estimate the setting-specific risk of multidrug-resistant tuberculosis among child cases of tu

41 The model for risk of multidrug-resistant tuberculosis among children with tub

42 ming increase in the number of patients with multidrug-resistant tuberculosis and extensively drug-re

43 focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacte

44 The increase in multidrug-resistant tuberculosis and high mortality amon

45 Approximately 50% of multidrug-resistant tuberculosis and over 90% of extensi

46 uenza, as well as emerging challenges (e.g., multidrug-resistant tuberculosis and pneumococcus).

47 improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread

48 Diagnosis of multidrug-resistant tuberculosis and prompt initiation o

49 outcomes for extensively drug-resistant and multidrug-resistant tuberculosis and the slow progress i

50 Multidrug-resistant tuberculosis and XDR tuberculosis gr

51 ence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 275% increase in

52 e tuberculosis, extrapulmonary tuberculosis, multidrug-resistant tuberculosis, and asymptomatic tuber

53 Secondary outcomes were missed tuberculosis, multidrug-resistant tuberculosis, and comorbidities with

54 luating new agents/regimens for treatment of multidrug-resistant tuberculosis; and (3) evaluating saf

55 ensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of acces

56 We evaluated the MDR-TB (multidrug-resistant tuberculosis) assay, which uses PCR-

57 327 patients were culture-positive for multidrug-resistant tuberculosis at baseline and compris

58 Multidrug-resistant tuberculosis at treatment initiation

59 well served by licensing of new regimens for multidrug-resistant tuberculosis based on biomarker evid

60 WGS diagnosed a case of multidrug-resistant tuberculosis before routine diagnosi

61 sis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated

62 by year, geographic region, tuberculosis or multidrug-resistant tuberculosis burden, and prison popu

63 e has been a wonder drug in the treatment of multidrug-resistant tuberculosis, but emergence of resis

64 lly, 4.6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, lik

65 n settings with more ongoing transmission of multidrug-resistant tuberculosis, but results were other

66 ing percentage reduction in the incidence of multidrug-resistant tuberculosis by 2024 compared with c

67 Community-based outpatient treatment of multidrug-resistant tuberculosis can yield high cure rat

68 Understanding why some multidrug-resistant tuberculosis cases are not detected

69 system increased referrals from presumptive multidrug-resistant tuberculosis cases by >10-fold, with

70 mmarize, a very high proportion of pulmonary multidrug-resistant tuberculosis cases in Los Angeles Co

71 s Angeles County by comparing relatedness of multidrug-resistant tuberculosis cases using restriction

72 ly a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the r

73 diagnosis was completed and discovered a new multidrug-resistant tuberculosis cluster.

74 idrug-resistant tuberculosis will be primary multidrug-resistant tuberculosis compared with only 15%

75 patient-reported outcomes for patients with multidrug-resistant tuberculosis, compared with usual ca

76 on control measures, and active screening of multidrug-resistant tuberculosis contacts, with prophyla

77 ovements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number

78 Health Organization outcome definitions for multidrug-resistant tuberculosis, cure rates at 120 week

79 ealthcare workers with the goal of improving multidrug-resistant tuberculosis detection.

80 derscore that many cases of tuberculosis and multidrug-resistant tuberculosis disease are not being d

81 orldwide population, the global incidence of multidrug-resistant tuberculosis disease in children has

82 to estimate regional and global incidence of multidrug-resistant tuberculosis disease in children in

83 cause many of these patients are at risk for multidrug-resistant tuberculosis, drug susceptibility te

84 The emergence and expansion of the multidrug-resistant tuberculosis epidemic is a threat to

85 atical models predict that the future of the multidrug-resistant tuberculosis epidemic will depend on

86 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

87 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

88 People with multidrug-resistant tuberculosis experience burdensome s

89 ecommends shortcourse regimen (SCR) to treat multidrug resistant tuberculosis for patients with strai

90 rge public health and societal implications, multidrug-resistant tuberculosis has been long regarded

91 Multidrug-resistant tuberculosis has emerged as a major

92 The increasing rate of multidrug-resistant tuberculosis has led to more use of

93 , rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to incre

94 rolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable ou

95 aquiline is a core drug for the treatment of multidrug-resistant tuberculosis; however, the understan

96 nurse-led palliative care for patients with multidrug-resistant tuberculosis improved self-reported

97 ns in the primary analysis, the incidence of multidrug-resistant tuberculosis in 2024 would be 3.3 (9

98 d the results of community-based therapy for multidrug-resistant tuberculosis in a poor section of Li

99 31 studies reported the risk of multidrug-resistant tuberculosis in both children and tr

100 the regional and global annual incidence of multidrug-resistant tuberculosis in children.

101 of the factors affecting the transmission of multidrug-resistant tuberculosis in HIV-endemic settings

102 ore proactive screening for tuberculosis and multidrug-resistant tuberculosis in inpatient settings i

103 Despite the prevalence of multidrug-resistant tuberculosis in nearly all low-incom

104 ent with individualized regimens for chronic multidrug-resistant tuberculosis in northern Lima.

105 eview what we know about the transmission of multidrug-resistant tuberculosis in settings with high b

106 Similar to the outbreaks of multidrug-resistant tuberculosis in the 1990s, poor infe

107 ounted for nearly one fourth of the cases of multidrug-resistant tuberculosis in the United States du

108 est number of patients with tuberculosis and multidrug-resistant tuberculosis in the world.

109 of isoniazid resistance, a 152% increase in multidrug-resistant tuberculosis incidence, a 242% incre

110 dations for the treatment of rifampicin- and multidrug-resistant tuberculosis include bedaquiline (BD

111 may have a role in the management of latent multidrug-resistant tuberculosis infection.

112 rculosis, and a 275% increase in the risk of multidrug-resistant tuberculosis infection.

113 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis

114 Multidrug-resistant tuberculosis is a major global healt

115 Multidrug-resistant tuberculosis is a man-made problem.

116 Multidrug-resistant tuberculosis is an increasing health

117 Preventing transmission of multidrug-resistant tuberculosis is critical because of

118 A case of multidrug-resistant tuberculosis is presented.

119 Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24

120 Multidrug-resistant tuberculosis is the result of the se

121 d-resistant tuberculosis is more common than multidrug-resistant tuberculosis, it has been much less

122 ope is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susc

123 The projected trajectory of multidrug resistant tuberculosis (MDR-TB) epidemics depe

124 Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, to

125 Multidrug resistant tuberculosis (MDR-TB) remains a glob

126 INTRODUCTION: Globally, multidrug resistant tuberculosis (MDR-TB) remains underd

127 Nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) has been repor

128 with multidrug chemotherapy to patients with multidrug-resistant tuberculosis (MDR TB) induces measur

129 For treating multidrug-resistant tuberculosis (MDR TB), the World Hea

130 f a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospect

131 part of combination therapy for treatment of multidrug-resistant tuberculosis (MDR TB).

132 fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB).

133 manid are newly available drugs for treating multidrug-resistant tuberculosis (MDR TB); however, ther

134 line Drug Resistance Emergence Assessment in Multidrug-resistant tuberculosis (MDR-TB) (DREAM) was a

135 former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are though

136 ed at our institution from 1983 to 1994 with multidrug-resistant tuberculosis (MDR-TB) and evaluated

137 have great potential to limit the spread of multidrug-resistant tuberculosis (MDR-TB) and extensivel

138 mpared chest radiographic characteristics of multidrug-resistant tuberculosis (MDR-TB) and non-tuberc

139 Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% o

140 ousehold contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high ri

141 We assessed multidrug-resistant tuberculosis (MDR-TB) cases and thei

142 The management of multidrug-resistant tuberculosis (MDR-TB) during pregnan

143 It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year.

144 n (RMP) and isoniazid (INH) and in detecting multidrug-resistant tuberculosis (MDR-TB) in comparison

145 patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russ

146 Multidrug-resistant tuberculosis (MDR-TB) is a major hea

147 Multidrug-resistant tuberculosis (MDR-TB) is an importan

148 Multidrug-resistant tuberculosis (MDR-TB) is associated

149 PZA resistance in multidrug-resistant tuberculosis (MDR-TB) is common and

150 Pyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet

151 infection among contacts of individuals with multidrug-resistant tuberculosis (MDR-TB) is controversi

152 Whether multidrug-resistant tuberculosis (MDR-TB) is less transm

153 Multidrug-resistant tuberculosis (MDR-TB) jeopardizes gl

154 Less than 30% of multidrug-resistant tuberculosis (MDR-TB) patients are c

155 antibiotics recommended for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients.

156 Multidrug-resistant tuberculosis (MDR-TB) poses a seriou

157 Multidrug-resistant tuberculosis (MDR-TB) presents an in

158 Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low glo

159 The incidence of multidrug-resistant tuberculosis (MDR-TB) remains critic

160 To realize the most benefit from multidrug-resistant tuberculosis (MDR-TB) screening, all

161 ion (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regi

162 Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-TB) treatment.

163 The alarming rise of multidrug-resistant tuberculosis (MDR-TB) underscores th

164 tion as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regi

165 Multidrug-resistant tuberculosis (MDR-TB), caused by dru

166 Multidrug-resistant tuberculosis (MDR-TB), defined as re

167 ay, a diagnostic test for rapid detection of multidrug-resistant tuberculosis (MDR-TB), in Rwanda.

168 Tuberculosis, including multidrug-resistant tuberculosis (MDR-TB), is a major gl

169 ip-based VerePLEX Biosystem for detection of multidrug-resistant tuberculosis (MDR-TB), obtaining a d

170 riptions of drug resistance in patients with multidrug-resistant tuberculosis (MDR-TB).

171 l impact of rapid diagnostic tests to detect multidrug-resistant tuberculosis (MDR-TB).

172 nes are the core drugs for the management of multidrug-resistant tuberculosis (MDR-TB).

173 All patients had multidrug-resistant tuberculosis (MDR-TB).

174 human immunodeficiency virus (HIV)/AIDS and multidrug-resistant tuberculosis (MDR-TB).

175 experiencing a regional increase in cases of multidrug-resistant tuberculosis (MDR-TB).

176 iazid (INH) resistance and used as proxy for multidrug-resistant tuberculosis (MDR-TB).

177 manid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, ther

178 that nonadherence is the proximate cause of multidrug-resistant tuberculosis (MDR-tuberculosis) emer

179 e the etiology of "hotspots" of concentrated multidrug-resistant tuberculosis (MDR-tuberculosis) risk

180 Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an o

181 Multidrug-resistant tuberculosis (MDRTB) has emerged as

182 at which most countries with high burdens of multidrug-resistant tuberculosis (MDRTB) have scaled up

183 The fitness of multidrug-resistant tuberculosis (MDRTB) relative to dru

184 ly been used to predict the future burden of multidrug-resistant tuberculosis (MDRTB).

185 s that have >5% prevalence (or incidence) of multidrug-resistant tuberculosis (MDRTB).

186 ive therapy on the contacts of patients with multidrug-resistant tuberculosis.Methods: In a prospecti

187 ith a confirmed bacteriological diagnosis of multidrug-resistant tuberculosis (not responsive to ison

188 health care worker, all of whom had AIDS) of multidrug-resistant tuberculosis occurred in a hospital

189 suicide gene especially for the treatment of multidrug-resistant tuberculosis once a delivery strateg

190 d be especially beneficial for patients with multidrug-resistant tuberculosis or extensively drug-res

191 Individuals with multidrug-resistant tuberculosis or missing data on race

192 esistance, one of which is associated with a multidrug-resistant tuberculosis outbreak in South Ameri

193 of net culture conversion were no history of multidrug-resistant tuberculosis (p=0.0007) and use of c

194 , as compared with 400 patients (66.3%) with multidrug-resistant tuberculosis (P=0.36).

195 We included 11 920 multidrug-resistant tuberculosis patients.

196 he public sector contributed 87% of acquired multidrug-resistant tuberculosis, related to irregular a

197 two MTBC strains isolated from patients with multidrug resistant tuberculosis, representing an as-yet

198 multiplied the setting-specific estimates of multidrug-resistant tuberculosis risk and tuberculosis i

199 agement of rifampicin-resistant tuberculosis/multidrug-resistant tuberculosis (RR-TB/MDR-TB).

200 t TB among people treated for rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB) are likely

201 Rifampin or multidrug-resistant tuberculosis (RR/MDR-TB) treatment h

202 Rifampin-resistant and/or multidrug-resistant tuberculosis (RR/MDR-TB) treatment r

203 nezolid, a component of rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment,

204 5 000-32 000 children develop rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB), and many m

205 te gut microbiome dynamics over 20 months of multidrug-resistant tuberculosis (TB) and 6 months of dr

206 globally distributed and is associated with multidrug-resistant tuberculosis (TB) and treatment fail

207 ntly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB).

208 ended in treatment regimens for rifampin- or multidrug-resistant tuberculosis (TB).

209 ay, 2016, WHO endorsed a 9 month regimen for multidrug-resistant tuberculosis that is cheaper and pot

210 rug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive

211 Multidrug-resistant tuberculosis threatens to reverse re

212 cal agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistan

213 human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, a

214 tients with newly diagnosed, smear-positive, multidrug-resistant tuberculosis to receive either 400 m

215 d eligible adults (>18 years) with pulmonary multidrug-resistant tuberculosis to receive, in combinat

216 each of confirmed tuberculosis and suspected multidrug-resistant tuberculosis) to a randomly allocate

217 tching on age, sex, geographic site, year of multidrug-resistant tuberculosis treatment initiation, p

218 Individualised multidrug-resistant tuberculosis treatment with novel (e

219 s associated with increased mortality during multidrug-resistant tuberculosis treatment, but the exte

220 V-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding th

221 s to follow-up, treatment failure, switch to multidrug-resistant tuberculosis treatment, or tuberculo

222 ic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment.

223 ations within lung cavities of patients with multidrug-resistant tuberculosis undergoing therapeutic

224 rld Health Organization category 5 drugs for multidrug-resistant tuberculosis using a 7H9 broth micro

225 CWs in 3 district hospitals with specialized multidrug-resistant tuberculosis wards in KwaZulu-Natal,

226 identified that the setting-specific risk of multidrug-resistant tuberculosis was nearly identical in

227 00, began to increase and focal outbreaks of multidrug-resistant tuberculosis were reported.

228 d sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a prefer

229 rospective cohort study of 608 patients with multidrug resistant tuberculosis who had treatment in ci

230 wed promising cure rates among patients with multidrug-resistant tuberculosis who received existing d

231 eport outcomes for a cohort of patients with multidrug-resistant tuberculosis who received high-dose

232 By 2032, an estimated 85% of multidrug-resistant tuberculosis will be primary multidr

233 We previously treated patients who had multidrug-resistant tuberculosis with recombinant IFN-ga

234 es in 205 patients treated at our center for multidrug-resistant tuberculosis, with strains resistant

235 ory of tuberculosis or household exposure to multidrug-resistant tuberculosis within the past 3 years